Vor Biopharma Inc. — Director's Dealing 2021

Feb 5, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Vor Biopharma Inc. (VOR)
CIK: 0001817229
Period of Report: 2021-02-04

Reporting Person: RA CAPITAL MANAGEMENT, L.P. (Director, 10% Owner)
Reporting Person: RA Capital Healthcare Fund LP (Director, 10% Owner)
Reporting Person: Kolchinsky Peter (Director, 10% Owner)
Reporting Person: Shah Rajeev M. (Director, 10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A-2 Preferred Stock	$		Common Stock (1644549)		Indirect
Series A-2 Preferred Stock	$		Common Stock (280330)		Indirect
Series B Preferred Stock	$		Common Stock (3784120)		Indirect
Series B Preferred Stock	$		Common Stock (1414026)		Indirect

Footnotes

F1: Each share of Series A-2 Preferred Stock and Series B Preferred Stock is convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 13.6-for-one basis, has no expiration date and will automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering.

F2: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3: These securities are held directly by RA Capital Nexus Fund, L.P. (the "Nexus Fund").

F4: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.